连续维奈克拉治疗复发慢性淋巴细胞白血病的长期结局
该研究纳入86例接受连续维奈克拉(±利妥昔单抗)治疗的复发/难治慢性淋巴细胞白血病患者,29例(33%)为长期缓解者(>5年无进展)。中位随访11.1年时76%已停药,主要因疾病进展;持续uMRD者5年PFS达87%,但全部患者存在持续复发、感染和血细胞减少风险。
要点
- 约三分之一复发/难治CLL患者可从连续维奈克拉治疗中获得>5年长期缓解。
- 持续uMRD是长期获益的最强预测指标,但所有患者仍有持续复发风险。
- 长期治疗中≥3级感染、中性粒细胞减少和血小板减少发生率保持稳定。
核心结论
- 连续维奈克拉治疗可使约三分之一复发/难治CLL患者获得>5年长期缓解,持续uMRD者结局最佳,但全部患者仍面临持续复发、感染和血细胞减少风险。
研究设计与样本
- 回顾性队列研究,从86例接受连续维奈克拉(±利妥昔单抗)治疗的复发/难治CLL患者中识别长期缓解者(>5年无进展),并进行2年和5年landmark分析及进展时二代测序。
主要发现
- 29例(33%)为长期缓解者,中位随访11.1年时76%已停用维奈克拉,主要因疾病进展。
- 长期缓解者较5年内进展者更常见IGHV突变(44% vs 14%;P = .029)、非复杂核型(89% vs 50%;P = .043)和uMRD(79% vs 30%;P < .001)。
- 在持续维奈克拉超过2年的患者中,uMRD者5年PFS为87%,无uMRD者为45%(风险比1.30;95%CI 1.12-1.52;P = .001)。
- 进展时8例中4例检出BCL2突变。
- ≥3级毒性包括感染(51%)、中性粒细胞减少(20%)和血小板减少(10%),在整个治疗期间发生频率保持一致。
关键数值与推荐
- uMRD定义为外周血流式细胞术检测MRD < 10⁻⁴。
- 长期缓解者定义为连续治疗>5年无进展性疾病。
临床怎么用
- 对复发/难治CLL患者,连续维奈克拉治疗可考虑作为长期治疗策略,但需监测uMRD以识别最可能长期获益者。
- 长期治疗期间需持续监测感染和血细胞减少,因≥3级毒性发生率保持稳定。
- 进展时建议进行BCL2和TP53突变检测以指导后续治疗。
局限性
- 回顾性队列研究,样本量有限(86例),长期缓解者仅29例。
- 来自单中心或特定队列,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax was first approved for continuous use in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), but the efficacy and consequences of very long-term BCL2 inhibition are unknown. We describe the frequency, characteristics, and outcomes of patients with R/R CLL treated with >5 years of continuous venetoclax. Long-term responders (>5 years of continuous therapy without progressive disease [PD]) were identified from a cohort of 86 patients with R/R CLL treated with continuous venetoclax with or without rituximab. Landmark analyses at 2 and 5 years assessed association between undetectable measurable residual disease (uMRD; 10-4 peripheral blood flow cytometry) and progression-free survival (PFS). Next-generation sequencing was performed at PD for BCL2 and TP53 mutations. Twenty-nine patients (33%) were long-term responders. Compared to those with PD within 5 years, they were more likely to have mutated immunoglobulin heavy chain variable region (44% vs 14%; P = .029), noncomplex karyotype (89 vs 50%; P = .043), and uMRD (79 vs 30%; P< .001). At a median follow-up of 11.1 years, 76% had discontinued venetoclax, mostly due to PD. In a landmark analysis of patients continuing venetoclax beyond 2 years, 5-year PFS was 87% for those with uMRD vs 45% without (hazard ratio, 1.30; 95% confidence interval, 1.12-1.52; P = .001). BCL2 mutations were detected in 4 of 8 patients at PD. Grade ≥3 toxicities, including infection (51%), neutropenia (20%), and thrombocytopenia (10%), occurred at consistent frequency throughout treatment. Long-term responses to continuous venetoclax occur in approximately one-third of patients with R/R CLL. Sustained uMRD confers the most favorable outcomes, although all patients show a continuous risk of relapse, infection, and cytopenias.
引用
- McKeague S, Lew TE, Lowe A, et al. Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia. Blood Adv. 2026. PMID: 42498281. doi:10.1182/bloodadvances.2026020789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。